AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$BCDA

BioCardia, Inc.

Price · $BCDAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $BCDA in the last 7 days.

Insider · 30dAll trades →
Buys
$8K
3 txs
Sells
—
0 txs
Altman Peter3× · $8K
10b5-1 share of filings0%
See all $BCDA insider activity →
Top stories · $BCDAMore →
AUG 19·fool.com

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

BioCardia (BCDA) reported Q2 2026 earnings with $4.1M in cash, a net loss of $1.6M, and raised $4.9M via ATM facility. The company reduced R&D spending and is progressing with regulatory submissions for CardiAMP in Japan and the U.S. Management anticipates market approval in Japan by Q4 2027 and FDA premarket approval support from ongoing trials. BioCardia is also exploring partnerships and streamlining trials to enhance enrollment.

BCDA sentiment & insider activity

Recent BCDA coverage spans insider activity and earnings.

In the last 30 days, BCDA insiders filed 3 SEC Form 4 transactions — 3 purchases ($8K) and no sales. The most active reporter was Altman Peter, President and CEO, with 3 filings.

What's driving BCDA

  • Small insider purchase likely has minimal immediate price impact.

    SEC EDGAR · Sep 5, 2026

  • Reduced loss and cash runway suggest improved financial health, while regulatory milestones could drive future upside.

    fool.com · Aug 19, 2026

  • Insider buying can be a modest sentiment tailwind, but this is a small, non-guidance insider transaction with limited fundamental signal.

    SEC EDGAR · Aug 18, 2026

  • The filing signals insider buying, but it is a small, non-guidance datapoint with limited direct impact on valuation.

    SEC EDGAR · Aug 13, 2026

  • Regulatory pathway clarity for CardiAMP in Japan and dual clearance pathways for the Helix catheter are near-term catalysts for de-risking timelines and financing needs.

    yahoo.com · Aug 13, 2026

alphai scores every news story that mentions BCDA with an AI model for sentiment and relevance, and aggregates insider trades from BioCardia, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BCDA

Score
AUG 19$BCDAMedfool.com

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

BioCardia (BCDA) reported Q2 2026 earnings with $4.1M in cash, a net loss of $1.6M, and raised $4.9M via ATM facility. The company reduced R&D spending and is progressing with regulatory submissions for CardiAMP in Japan and the U.S. Management anticipates market approval in Japan by Q4 2027 and FDA premarket approval support from ongoing trials. BioCardia is also exploring partnerships and streamlining trials to enhance enrollment.

3 min read
AUG 13$BCDAMedyahoo.com

BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan

BioCardia (BCDA) reported Q2 2026 regulatory updates for its CardiAMP cell therapy and Helix delivery catheter. According to management, Japan’s PMDA supported a Shonin premarket submission, with approval expected about 12 months after filing. The FDA said CardiAMP Heart Failure 2 could support premarket approval and outlined two Helix clearance pathways. Q2 2026 net cash used in operations was ~$1.7M; cash ended at ~$5.4M.

4 min read
AUG 12$BCDAMedSEC EDGAR 8-K

BioCardia, Inc. (BCDA): Results of Operations and Financial Condition

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results Sunnyvale, Calif. – August 12, 2026 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,

6 min read

Related tickers

More in Biotechnology